Hexarelin vs GHRP-6: Potency, Dosing & Research Protocol Comparison 2026

> Research Use Only Disclaimer: Hexarelin and GHRP-6 are research peptides not approved by the FDA for human use. All information, protocols, and comparative data in this article are sourced from peer-reviewed scientific literature and are provided strictly for educational and research purposes. This article does not constitute medical advice. Do not administer these or any research peptides to humans.

Both hexarelin and GHRP-6 are growth hormone-releasing peptides (GHRPs) that stimulate pulsatile GH secretion by activating the ghrelin receptor (GHSR-1a). Yet they differ markedly in potency, side effect profile, receptor pharmacology, and practical research utility. This guide compares them directly — covering mechanism, GH output, appetite effects, desensitization, stacking, and which compound fits which research context.

---

1. Overview: What Are GHRPs?

Growth hormone-releasing peptides (GHRPs) are a class of synthetic peptides that mimic endogenous ghrelin's ability to stimulate growth hormone (GH) secretion from the pituitary. Unlike GHRH analogs (which amplify the GHRH signal from the hypothalamus), GHRPs act directly at GHSR-1a receptors on both hypothalamic neurons and pituitary somatotrophs — producing robust, acute GH pulses.

The GHRP family includes:

• •GHRP-6 — the original and most-studied GHRP; strong appetite stimulation
• •GHRP-2 (Pralmorelin) — second-generation; higher potency than GHRP-6, less appetite effect
• •Hexarelin (Examorelin) — third-generation; the most potent GHRP; rapid desensitization
• •Ipamorelin — most selective; weakest GH release; no cortisol/prolactin; minimal appetite

Hexarelin and GHRP-6 represent opposite ends of the GHRP potency-selectivity spectrum, making a direct comparison particularly useful for researchers designing GH axis studies.

---

2. Hexarelin: Deep Dive

Mechanism and Receptor Pharmacology

Hexarelin (sequence: His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide developed in the 1990s by Europeptides. It binds GHSR-1a with the highest affinity of any synthetic GHRP — roughly 3–5× greater than GHRP-6 — and produces the largest acute GH pulses of any compound in its class.

Uniquely among GHRPs, hexarelin also activates:

• •CD36 (scavenger receptor B2): mediates direct cardioprotective effects independent of GH secretion
• •Cardiovascular GHSR isoforms: hexarelin reduces ischemia-reperfusion injury, improves cardiac output, and attenuates cardiomyocyte apoptosis — effects that persist in hypophysectomized animals, confirming GH-independent mechanisms (Mao et al., 2007; Broglio et al., 2003)

This dual GHSR-1a/CD36 activity makes hexarelin the only GHRP with a documented cardiac research application separate from its GH-axis effects.

GH Pulse Magnitude

Human clinical data (Arvat et al., 1997) demonstrates that hexarelin at 2 mcg/kg IV produces peak GH concentrations of 60–100 ng/mL — 2–3× higher than GHRP-2 and approximately 4–5× higher than GHRP-6 at equivalent molar doses. The GH area under the curve (AUC) is correspondingly elevated.

Cortisol and Prolactin Co-Release

Hexarelin's high GHSR-1a efficacy also stimulates HPA axis activation — resulting in meaningful cortisol and prolactin co-release. Studies show:

• •Cortisol increases of 40–80% above baseline following hexarelin administration
• •Prolactin elevations of 20–50% above baseline

For research designs where GH axis isolation is required, this hormonal cross-activation can confound results. Researchers studying pure GH dynamics often switch to ipamorelin (which has no cortisol/prolactin effect) for this reason.

Desensitization: Hexarelin's Key Limitation

Hexarelin's potency is its primary liability in sustained research protocols. Pituitary GH responses decline significantly with repeated daily dosing — typically 30–60% attenuation within 2–4 weeks of continuous use (Ghigo et al., 1994; Loche et al., 1997). This rapid desensitization is attributed to GHSR-1a downregulation driven by hexarelin's high receptor occupancy and efficacy.

Practical research implication: hexarelin is most effective in short-duration, high-stimulus protocols (1–2 week acute studies) rather than chronic GH augmentation models.

Typical Hexarelin Research Protocols

• •Dose range: 100–200 mcg per administration (subcutaneous injection)
• •Frequency: 1–3× daily (fasted state; 45–60 min post-injection for GH peak)
• •Cycle duration: 4–8 weeks maximum to minimize desensitization (with 4-week off periods)
• •Stacking: Most commonly paired with CJC-1295 (with DAC) or Sermorelin for synergistic GH axis amplification

For the complete hexarelin dosage reference, see our Hexarelin Dosage Protocol Guide 2026.

---

3. GHRP-6: Deep Dive

Mechanism and Receptor Pharmacology

GHRP-6 (sequence: His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂) is the original synthetic GHRP, first synthesized in the 1980s by Bowers et al. and the foundational compound in GHRP research. Like all GHRPs, it acts as a GHSR-1a agonist — but with lower receptor affinity than hexarelin or GHRP-2.

GHRP-6 is a selective ghrelin mimetic with no documented CD36 or off-target cardiac receptor activity. Its pharmacological profile is essentially confined to:

• •GHSR-1a agonism → GH secretion
• •Mild HPA axis stimulation → moderate cortisol/prolactin co-release
• •Strong ghrelin pathway activation → pronounced appetite stimulation

GH Pulse Magnitude

GHRP-6 produces GH pulses substantially lower than hexarelin. In comparative studies, GHRP-6 at 1–2 mcg/kg IV generates peak GH concentrations of 15–35 ng/mL — significant but roughly 3–5× lower than hexarelin at equivalent doses. For research requiring moderate GH stimulation without the desensitization risks of more potent GHRPs, GHRP-6 occupies a useful middle ground.

Cortisol and Prolactin Co-Release

Like hexarelin (though to a lesser degree), GHRP-6 stimulates modest cortisol and prolactin co-release:

• •Cortisol: 20–40% above baseline
• •Prolactin: 10–30% above baseline

These elevations are generally lower than hexarelin's but higher than GHRP-2 for cortisol, and similar to GHRP-2 for prolactin. Pure GH axis research designs should account for this hormonal cross-talk.

Appetite Stimulation: GHRP-6's Defining Feature

GHRP-6 is the strongest appetite stimulant of all GHRPs — typically producing intense hunger ("ghrelin hunger") 30–45 minutes post-injection. This effect stems from GHRP-6's ghrelin-mimetic properties: ghrelin itself is a potent appetite hormone, and GHRP-6's structural similarity produces a pronounced orexigenic response.

Research implications:

• •Appetite/weight models: GHRP-6 is the preferred GHRP for studies examining ghrelin's orexigenic pathway, diet-induced obesity models, or caloric intake research
• •Interference risk: In GH-only research, GHRP-6's appetite effect can complicate feeding behavior data — hexarelin or GHRP-2 produce less appetite stimulation
• •Muscle/weight gain models: The appetite co-stimulus may be considered a feature in anabolic/body composition models where increased caloric intake is desired

Desensitization: More Favorable Than Hexarelin

GHRP-6's lower GHSR-1a efficacy results in a more favorable desensitization profile compared to hexarelin. GH response attenuation is slower — typically occurring over 4–8 weeks of continuous dosing rather than the 2–4 weeks seen with hexarelin. This makes GHRP-6 a more sustainable choice for longer-duration GH secretagogue studies.

Typical GHRP-6 Research Protocols

• •Dose range: 100–300 mcg per administration (subcutaneous injection)
• •Frequency: 2–3× daily (fasted state; on empty stomach for strongest response)
• •Cycle duration: 8–12 weeks (longer sustainable cycle vs. hexarelin due to slower desensitization)
• •Stacking: Commonly combined with CJC-1295 or Sermorelin; also used in appetite research as monotherapy

For the complete GHRP-6 dosage reference, see our GHRP-6 Dosage Protocol Guide 2026.

---

4. Head-to-Head Comparison Table

---

5. Which to Use for Which Research Context

Choose Hexarelin When:

Maximal acute GH stimulation is required

Hexarelin is the gold standard when peak GH pulse amplitude is the primary research outcome. If your model requires the highest achievable GH secretion from a GHRP, hexarelin is the appropriate choice. Typical contexts: GH secretory capacity testing, pituitary responsiveness studies, comparative GH secretagogue pharmacology.

Cardiac and cardioprotective research

Hexarelin's CD36 activity and direct cardiac receptor binding make it uniquely suited for ischemia-reperfusion injury models, cardiac function studies, and cardiomyocyte protection research. No other GHRP shares this profile.

Short-duration, high-intensity protocols

For acute (1–2 week) studies where maximum stimulus is needed and desensitization is not a long-term concern, hexarelin's potency advantage is most efficiently leveraged.

GHSR-1a receptor pharmacology studies

Hexarelin's high receptor affinity makes it useful as a reference agonist in receptor binding and competition assays.

Choose GHRP-6 When:

Appetite, orexigenic pathway, or feeding behavior research

GHRP-6 is the definitive GHRP for studies examining ghrelin's appetite-stimulating mechanism. Its strong orexigenic effect provides a reliable, reproducible model for ghrelin-mediated hunger, weight gain, and metabolic research.

Longer-duration GH secretagogue studies

GHRP-6's slower desensitization curve makes it more practical for sustained GH research protocols spanning 8–12 weeks. Hexarelin's rapid receptor downregulation limits its usefulness in chronic models.

Cost-sensitive protocols

GHRP-6 is generally less expensive than hexarelin per dose, making it economical for high-volume or large animal studies where per-dose cost matters.

Foundational/comparative GHRP reference

As the original GHRP with the largest human clinical literature base, GHRP-6 is the canonical compound when replicating or extending established research protocols.

Either Compound Works For:

• •Combined GHRH/GHRP stacking protocols (synergistic GH amplification)
• •GH pulse timing and frequency studies
• •Pituitary somatotroph response characterization
• •Comparative GHRP pharmacology within a larger panel (alongside GHRP-2, ipamorelin)

---

6. Stacking Protocols: Combining GHRPs with GHRH Analogs

Both hexarelin and GHRP-6 produce significantly larger GH pulses when combined with a GHRH analog (CJC-1295 or Sermorelin). This is because GHRPs act via a different receptor pathway than GHRH — their co-administration produces synergistic (not merely additive) GH release.

Mechanism of synergy:

• •GHRH analogs (CJC-1295, Sermorelin) prime pituitary somatotrophs by amplifying the GHRH signal
• •GHRPs then trigger pulsatile GH release from the primed somatotrophs
• •Combined, the two pathways produce GH pulses 2–3× larger than either compound alone

Hexarelin + CJC-1295 Stack

The most potent GHRP/GHRH combination available in the research context:

• •Hexarelin: 100 mcg SC
• •CJC-1295 (with DAC): 1,000–2,000 mcg 1–2×/week (long-acting; maintains GHRH background)
• •Administration: Inject hexarelin in the fasted state; CJC-1295 DAC on its own schedule
• •Expected GH output: Substantially amplified vs. hexarelin alone
• •Caution: This combination produces very high cortisol co-release; researchers should account for HPA axis activation in study design

Hexarelin + Sermorelin Stack

A shorter-acting alternative:

• •Hexarelin: 100–150 mcg SC
• •Sermorelin: 200–400 mcg SC (co-administered or 15 min prior)
• •Administration: 2–3× daily, fasted
• •Expected GH output: High; less sustained than CJC-1295 DAC stack due to Sermorelin's short half-life

GHRP-6 + CJC-1295 Stack

The classic longer-duration research stack:

• •GHRP-6: 100–200 mcg SC
• •CJC-1295 (with DAC): 1,000–2,000 mcg 1–2×/week
• •Administration: GHRP-6 2–3× daily (fasted); CJC-1295 DAC weekly or bi-weekly
• •Expected GH output: 2–3× GHRP-6 monotherapy
• •Practical advantage: Slower desensitization than hexarelin stack; suitable for 10–12 week protocols

GHRP-6 + Sermorelin Stack

For researchers who prefer shorter-acting GHRH components:

• •GHRP-6: 100–200 mcg SC
• •Sermorelin: 200–400 mcg SC (co-injected)
• •Frequency: 2–3× daily, fasted
• •Advantage: Both components clear rapidly, simplifying washout period design

---

7. Pricing and Availability

Both hexarelin and GHRP-6 are widely available from research peptide suppliers. GHRP-6 is generally the more affordable of the two — reflecting its longer market history and lower synthesis complexity. Hexarelin commands a premium given its higher potency per dose and more complex manufacturing.

For current supplier pricing and real-time cost comparison, visit our peptide price comparison tool which aggregates pricing across verified research peptide suppliers.

General pricing hierarchy (most to least expensive per mg):

Hexarelin > GHRP-2 > GHRP-6 > Ipamorelin

Bulk purchasing typically reduces per-mg cost by 30–50% for high-volume research programs. Always verify supplier quality through independent third-party COAs (certificates of analysis) and HPLC purity data before procurement.

---

8. Summary: Hexarelin vs. GHRP-6 at a Glance

---

References

1. Arvat E, et al. "Hexarelin, a new synthetic GH-releasing peptide, is a potent stimulator of GH secretion in both humans and animals." Journal of Endocrinology (1997).

2. Ghigo E, et al. "Desensitization to the GH-releasing effect of hexarelin but not to that of GRF in normal subjects." European Journal of Endocrinology (1994).

3. Mao Y, et al. "Hexarelin protects cardiomyocytes from oxidative stress-induced apoptosis." Endocrinology (2007).

4. Bowers CY, et al. "Growth hormone-releasing peptide (GHRP-6): biological activities and clinical applications." Endocrinology (1991).

5. Loche S, et al. "Repeated administration of hexarelin in children with GH deficiency." Journal of Clinical Endocrinology & Metabolism (1997).

6. Broglio F, et al. "The endocrine and non-endocrine activities of hexarelin, a synthetic hexapeptide." European Journal of Endocrinology (2003).

---

> Disclaimer: Hexarelin and GHRP-6 are research compounds intended for in vitro and preclinical in vivo research use only. They are not approved by the FDA or any regulatory body for human use. The information in this article is for educational and scientific reference purposes only and does not constitute medical advice. Researchers should consult applicable regulations and institutional review protocols before use in any study.